Skip to main content
Fachgebiete
Automobil + Motoren Bauwesen + Immobilien Business IT + Informatik Elektrotechnik + Elektronik Energie + Nachhaltigkeit Finance + Banking Management + Führung Marketing + Vertrieb Maschinenbau + Werkstoffe Versicherung + Risiko
DE
EN
Bücher
Zeitschriften
Themenseiten
Organisationspsychologie Projektmanagement Marketing Smart Manufacturing
Weitere Formate
Podcasts Webinare Technik Webinare Wirtschaft Kongresse Veranstaltungskalender Awards
Jetzt Einzelzugang starten
Zugang für Unternehmen
Referenzkunden
SLX-Digitalkonferenz: Zukunftswerkstatt 2024

Mehr Umsatz mit Top-Kontakten

Am 7. Mai erfahren Sie, wie Vertriebsteams Leadgenerierung, Leadnurturing und Leadstrategien effizient steuern können.
Erweiterte Suche
Anmelden
nach oben
Erschienen in:
Why Green and Sustainable Pharmacy? Kapitel lesen Erstes Kapitel lesen

2010 | OriginalPaper | Buchkapitel

3. Pharmaceuticals in Society

verfasst von : David J. Triggle

Erschienen in: Green and Sustainable Pharmacy

Verlag: Springer Berlin Heidelberg

Einloggen

Aktivieren Sie unsere intelligente Suche, um passende Fachinhalte oder Patente zu finden.

search-config
loading …

Abstract

The great discoveries in biology of the twentieth century have enormous potential to improve global health. There are, however, many challenges. How do we handle the fact that one billion people are overweight and obese while one billion are undernourished? That drugs for poor people are often considered to be a bad investment? Sick care or health care? Can health care be delivered effectively through a profit-driven “free market” system? What will be the role of pharmaceuticals in the twenty-first century? This role must be considered not only from a scientific perspective, but also from global social and economic perspectives.

Sie haben noch keine Lizenz? Dann Informieren Sie sich jetzt über unsere Produkte:

Springer Professional "Wirtschaft+Technik"

Online-Abonnement

Mit Springer Professional "Wirtschaft+Technik" erhalten Sie Zugriff auf:

  • über 102.000 Bücher
  • über 537 Zeitschriften

aus folgenden Fachgebieten:

  • Automobil + Motoren
  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Elektrotechnik + Elektronik
  • Energie + Nachhaltigkeit
  • Finance + Banking
  • Management + Führung
  • Marketing + Vertrieb
  • Maschinenbau + Werkstoffe
  • Versicherung + Risiko

Jetzt Wissensvorsprung sichern!

Jetzt informieren

Springer Professional "Technik"

Online-Abonnement

Mit Springer Professional "Technik" erhalten Sie Zugriff auf:

  • über 67.000 Bücher
  • über 390 Zeitschriften

aus folgenden Fachgebieten:

  • Automobil + Motoren
  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Elektrotechnik + Elektronik
  • Energie + Nachhaltigkeit
  • Maschinenbau + Werkstoffe




 

Jetzt Wissensvorsprung sichern!

Jetzt informieren
Vorheriges Kapitel Pharmaceuticals in the Environment: Moving from a Problem to a Solution
Nächstes Kapitel Green(er) Pharmacy
Literatur
Angell M (2004) The Truth About Drug Companies. Random House, New York
Arrow KJ (1963) Uncertainty and the welfare economics of medical care. Am Econ Rev LIII, 941–973
Baker D (2008) Getting more for less. The not-so-obvious benefit of publicly funded trials for new drugs. The Milken Institute Review, Third Quarter, 46–53
Brandt AM (2007) The Cigarette Century. Perseus Books, New York
Bray GA, Tartaglia LA (2000) Medicinal strategies in the treatment of obesity. Nature 404,672–677
Brookes M (2004) Extreme Measures. Bloomsbury Books, London
Burd-Sharps S, Lewis K, Martins EB (2008) The Measure of America. American Human Development Report, 2008–2009. Columbia University Press, New York
Callahan D, Wasunna AA (2006) Medicine and the Market. Equity v. Choice. Johns Hopkins University Press, Baltimore, MD
Couzin-Frankel J (2009) The promise of a cure: 20 years and counting. Science 324, 1504–1507CrossRef
Cuatrecasas P (2006) Drug discovery in jeopardy. J Clin Invest 116, 2837–2842CrossRef
De Angelis C, et al. (2004) Clinical trial registration: A statement from the International Committee of Medical Journal Editors. N Engl J Med 352, 2436–2438CrossRef
DiMasi JA, Hansen RW, Grabowski HG (2003) J Health Econ 22, 151–185CrossRef
Editorial Nature Biotechnology (2004) Drugs in crops – the unpalatable truth. Nat Biotechnol 22,~133CrossRef
Ehrlich P (1959) Papers reprinted in the collected papers of Paul Ehrlich. In: Himmelweit F, Marquardt M, Dale HH (eds.) Chemotherapy 3. Pergamon Press, Press, London, pp. 505–518
Farmer P (1999) Infections and Inequalities. The Modern Plagues. California University Press, Berkeley, CA
Finkelstein S, Temin P (2008) Reasonable Rx: Solving the Drug Price Crisis. FT Press, London and New York
Friedman JM (2000) Obesity in the new millennium. Nature 404, 632–634
General Accounting Office (2006) New Drug Development. Science, business, regulatory, and intellectual property issues cited as hampering drug development efforts. GAO-07-49. http://​www.​gao.​gov
Grabowski H (2008) Follow-on biologics: Data exclusivity and the balance between innovation and competition. Nat Rev Drug Discov 7, 479–488CrossRef
Hegde BM (2005) Modern medicine – A boon or a bane. Kuwait Med J 37, 235–237, December
Heller M (2008) Gridlock Economy. How Too Much Ownership Wrecks Markets, Stops Innovation and Costs Lives. Basic Books, New York
Heller M, Eisenberg RS (1998) Can patents deter innovation? The anti-commons in biomedical research. Science 280, 698–701CrossRef
Hellerstein MK (2008) A critique of the molecular target-based drug discovery paradigm based on principles of metabolic control. Advantages of pathway-based drug discovery. Metab Eng 10, 1–9CrossRef
Herrling P (2006/2007) Building innovative partnerships in neglected disease research. Drug Discov World, 22–25, Winter
Hertzman C (2001) Health and human society. Am Sci 89, 538–545
Johnson S (2006) The Ghost Map. Riverhead Books, New York
Huxley A (1932) Brave New World. Harper Row, New York
Judson H (1979) The Eighth Day of Creation: Makers of the Modern Revolution in Biology. Simon and Schuster, New York
Karlberg JPE (2008) Trends in disease focus of drug development. Nat Rev Drug Discov 7, 639–640CrossRef
Kopelman PG (2000) Obesity as a medical problem. Nature 404, 635–643
Leranth C, Hajszan T, Szigeti-Buck K, Bober J, MacLusky NJ (2008) Bisphenol a prevents the synaptogenic response to estradiol in hippocampus and prefrontal cortex of ovariectomized nonhuman primates. Proc Natl Acad Sci USA 105, 14187–14191CrossRef
Li JE-H, Vederas JC (2009) Drug discovery and natural products: End of an era or an endless frontier? Science 325, 161–165CrossRef
Manheim BS, Jr, Ranahan P, Dow KJ (2006) “Follow-on biologics”: Ensuring continued innovation in the biotechnology industry. Health Affairs 26, 394–404CrossRef
McKibben B (2003) Enough. Staying human in an engineered age. Holt and Company, New York
Mello MM, Studdert DM, Brennan TA (2006) Obesity – the new frontier of public health law. N Engl J Med 354, 2601–2610CrossRef
Moynihan R, Cassels A (2005) Selling Sickness. Nation Books, New York
Moynihan R (2006) Scientists find new disease: Motivational deficiency disorder. BMJ 332, 745CrossRef
Moynihan R (2008) Disease mongering is now part of the global health debate. PLoS Med 5, 0684–0686CrossRef
Nestle M (2006) Food marketing and childhood obesity – a matter of policy. N Engl J Med 354, 2527–2529CrossRef
Noble D (2008) Claude Bernard, the first systems biologist, and the future of physiology. Exp Physiol 93, 16–26CrossRef
Nolte E, McKee CM (2008) Measuring the health of nations: Updating an earlier analysis. Health Affairs 27, 58–71
Roberts L, Simpson S (2008) Deadly defiance. A series of articles on drug resistance. Science 321, 355–369CrossRef
Sachs JD (2005) The End of Poverty. Economic Possibilities for Our Time. Penguin Press,New York
Schlosser E (2001) Fast Food Nation. The Dark Side of the All-American Meal. Houghton Miflin, New York
Schmid EF, Smith DA (2007) Pharmaceutical R&D in the spotlight: Why is there still unmet medical need? Drug Discov Today 12, 998–1006CrossRef
Smith JS (1990) Patenting the Sun. Polio and the Salk Vaccine. William Morrow, New York
Satrfield B (2000) Is US health really the best in the world? JAMA 284, 483–485CrossRef
Stuckler D, King LP, Basu S (2008) International monetary fund programs and tuberculosis outcomes in post-communist countries. PLoS Med 5, 1079–1090CrossRef
Triggle DJ (2003) Medicines in the 21st Century. Drug Dev Res 59, 269–291
Triggle DJ (2005a) Vaccines, viagra and vioxx: Medicines, markets and money – when life-saving meets life-style. Drug Dev Res 64, 90–98CrossRef
Triggle DJ (2005b) Patenting the sun: Enclosing the scientific commons and transforming the university – ethical concerns. Drug Dev Res 63, 139–149CrossRef
Triggle DJ (2006) Treating desires not diseases: A pill for every ill and an ill for every pill? Drug Discov Today 12, 161–166CrossRef
Triggle DJ (2009) The chemist as astronaut: Searching for biologically useful space in the chemical universe. Biochem Pharmacol 78, 217–223CrossRef
Tucker TJ, Makgoba MW (2008) Public-private partnerships and scientific imperialism. Science 320, 1016–1017CrossRef
Vandenberg LN, Maffini MV, Sonnenschein C, Rubin BS, Soto AM (2009) Bisphenol-A and the great divide: A review of controversies in the field of endocrine disruption. Endocrine Reviews 30, 75–95
Wadman M (2005) Path to approval proves rocky for copycat biodrugs. Nature 438, 154–155CrossRef
Walsh G, Jefferis R (2006) Post-translational modifications in the context of therapeutic proteins. Nat Biotechnol 24, 1241–1252CrossRef
Wilkinson RG (2000) Mind the Gap. Hierarchies, Health and Evolution. Yale University Press, New Haven
Wilkinson RG, Pickett KE (2006) Income inequality and population health: A review and explanation of the evidence. Social Sci Med 62, 1768–1784CrossRef
Williams M (2004) A return to the fundamentals of drug discovery? Curr Opin Invest Drugs 5, 29–33
Metadaten
Titel
Pharmaceuticals in Society
verfasst von
David J. Triggle
Copyright-Jahr
2010
Verlag
Springer Berlin Heidelberg
Buch
Green and Sustainable Pharmacy

Print ISBN: 978-3-642-05198-2

Electronic ISBN: 978-3-642-05199-9

Copyright-Jahr: 2010

DOI
https://doi.org/10.1007/978-3-642-05199-9_3